Watch as Dr. Michael Elliott, Chief of Neurology at the Swedish Neuroscience Institute, shares his personal experiences and best practices for the diagnosis and management of ALS.
See patient and caregiver experiences with RADICAVA®.
Learn more
FDA recognizes RADICAVA ORS® as MAJOR CONTRIBUTION TO PATIENT CARE1. To learn more, Download brochure.
ALS Expert Video Library
Learn more about RADICAVA ORS® (edaravone) and RADICAVA® (edaravone) IV for the treatment of ALS through a series of educational videos.
Hear From Your Peers
Experienced neurologists provide their insights for considering RADICAVA® treatment that has been prescribed by 2400+ US HCPs since August 2017.1 a (see footnote)
Providers are paid consultants.
Featured video—Experiences of an ALS Expert, Featuring Dr. Michael Elliott
Experiences of an ALS Expert, Featuring Dr. Michael Elliott
Dosing and administration of RADICAVA ORS®
Learn about the dosing and administration of RADICAVA ORS®, the oral formulation of RADICAVA®, in this video featuring Dr. Michael Elliott.
Dosing and administration of RADICAVA ORS®
The Safety and Efficacy of RADICAVA® IV (edaravone) and RADICAVA ORS®
Watch Dr Michael Elliott, Chief of Neurology for the Swedish Neuroscience Institute, provide a clinical overview of the Efficacy and Safety of RADICAVA® IV and RADICAVA ORS®.
The Safety and Efficacy of RADICAVA® IV (edaravone) and RADICAVA ORS®
Nationwide Webcast Video Discussion About a Treatment in ALS
Stanley H. Appel, MD, and Gary L. Pattee, MD, discuss RADICAVA ORS® data and their thoughts on what oral treatment means to patients.
Nationwide Webcast Video Discussion About a Treatment in ALS
Considerations When Prescribing
Ghazala Hayat, MD, FAAN, explains why she recommends RADICAVA® for all of her patients who are newly diagnosed with ALS and how the inclusion criteria from the pivotal trial impacts her decision to prescribe treatment.
Considerations When Prescribing
The Efficacy of RADICAVA®
Said Beydoun, MD, FAAN, discusses clinical trial results of RADICAVA®, his use of the ALSFRS-R with his patients, and the challenges that have faced previous ALS clinical trials and how newer clinical trials are addressing them.
The Efficacy of RADICAVA®
Incorporating RADICAVA® Into Your Treatment Considerations
Tomas Holmlund, MD, shares advice for handling in-office practicalities with RADICAVA®, including insurance and product access, and he explains why some of his patients prefer receiving treatment at an infusion center.
Incorporating RADICAVA® Into Your Treatment Considerations
Safety and Personal Experience When Prescribing
Tomas Holmlund, MD, discusses the safety profile of RADICAVA® and how it impacts his decision to prescribe treatment.
Safety and Personal Experience When Prescribing
Add your practice to our ALS Care Locator.
Presentations
A panel of ALS experts discuss the benefits, risks, and appropriate uses of RADICAVA ORS® or RADICAVA® IV.
Providers are paid consultants.
Dr. Trevor J. Resnick
Clinical Professor, Department of Neurology
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida
Dr. Caralayne Jackson
University of Texas Health Science Center
San Antonio, Texas
Dr. Jonathan Katz
California Pacific Medical Center
San Francisco, California
ALS Functional Rating Scale-Revised
Learn about the ALS Functional Rating Scale-Revised (ALSFRS-R), the measure used to evaluate the clinical efficacy of RADICAVA®.
ALS Functional Rating Scale-Revised
Pivotal Trial in ALS
Review information on the pivotal trial of RADICAVA® in ALS, including the clinical development program, key inclusion criteria, and baseline patient characteristics.
Pivotal Trial in ALS
Efficacy and Safety
Hear about primary efficacy endpoint data and safety information from the pivotal trial of RADICAVA®.
Efficacy and Safety
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of May 2024. Not independently verified. Return to content
Reference: 1. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.
Explore detailed results of the pivotal trials that were discussed.
